Drugs / Artemisinin
Artemisinin
also known as
Artemisinina · Artemisinine · Artemisininum · GNF-PF-5341 · Huanghuahaosu · NSC-369397 · Qing hau sau
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01391403 | Sep 2008 → Apr 2011 | schizophrenia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05004753 | Sep 2020 → Feb 2021 | COVID-19 | Mateon Therapeutics | Completed | No outcome recorded |
| Phase 4 | NCT01930331 | Jan → Jul 2014 | Plasmodium falciparum malaria | Ifakara Health Institute | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04801017 Background | Apr → Aug 2021 | COVID-19 | Oncotelic Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2021-08-24 | Mateon Therapeutics | Results PULMOHEAL™/ ARTIVEDA™ IS CLINICALLY ACTIVE AGAINST MILD AND MODERATE COVID-19. oncotelic.com ↗
artemisinin+SOC group showed significant improvement over SOC in WHO severity scale on Day 4 and Day 5 with p=0.0045 and p=0.0370, respectively. |
| 2021-03-01 | Mateon Therapeutics | Results MATEON THERAPEUTICS AND WINDLAS BIOTECH PUBLISH PULMOHEAL™ CLINICAL DATA AGAINST COVID-19 IN PEER-REVIEWED JOURNALS oncotelic.com ↗
More patients recovered faster when PulmoHeal TM was used as adjunct therapy alongside standard of care (SOC). |
| 2021-02-02 | Mateon Therapeutics | Results MATEON ANNOUNCES COMPLETION OF ARTI-19 AND PUBLICATION OF POSITIVE INTERIM DATA oncotelic.com ↗
When ARTIVeda ™ / PulmoHeal ™ was added to the standard of care (SOC), more patients recovered faster than SOC alone. |
| 2020-10-05 | Mateon Therapeutics | Regulatory MATEON THERAPEUTICS TO INITIATE COMMERCIALIZATION OF ARTISHIELD™. oncotelic.com ↗
Mateon Therapeutics "Mateon" (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced that ArtiShield TM is now approved for manufacture and marketing by the Ministry of AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy), license number UK.AY-401/2018, for the treatment of various symptoms like fever and inflammation. |
| 2020-09-14 | Mateon Therapeutics | Regulatory MATEON oncotelic.com ↗
Mateon Therapeutics "Mateon" (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that its global study based on its ARTI-19 protocol for Artemisinin Intervention against COVID-19 has been cleared for patient enrollment in India. |
All press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-08-24 | Mateon Therapeutics | PULMOHEAL™/ ARTIVEDA™ IS CLINICALLY ACTIVE AGAINST MILD AND MODERATE COVID-19. oncotelic.com ↗ |
| 2021-03-01 | Mateon Therapeutics | MATEON THERAPEUTICS AND WINDLAS BIOTECH PUBLISH PULMOHEAL™ CLINICAL DATA AGAINST COVID-19 IN PEER-REVIEWED JOURNALS oncotelic.com ↗ |
| 2021-02-02 | Mateon Therapeutics | MATEON ANNOUNCES COMPLETION OF ARTI-19 AND PUBLICATION OF POSITIVE INTERIM DATA oncotelic.com ↗ |
| 2020-10-05 | Mateon Therapeutics | MATEON THERAPEUTICS TO INITIATE COMMERCIALIZATION OF ARTISHIELD™. oncotelic.com ↗ |
| 2020-09-14 | Mateon Therapeutics | MATEON oncotelic.com ↗ |
| 2020-08-04 | Mateon Therapeutics | MATEON THERAPEUTICS AND ABIOGENESIS TO INITIATE CLINICAL STUDY TO TEST ARTEMISININ AS A TREATMENT FOR COVID-19 IN INDIA oncotelic.com ↗ |
| 2020-07-20 | Mateon Therapeutics | MATEON AND ASILI RESEARCH ALLIANCE ENTER INTO PARTNERSHIP FOR THE DEVELOPMENT OF ARTEMISININ AGAINST COVID-19 oncotelic.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | artemisinin | “Subject's compliance with the study treatment regimen of Artemisinin one (1) capsule a day for five (5) days, will be assessed during treatment period.” NCT05004753 ↗ |
| Known as | Artemisinina | ChEMBL registry synonym — accepted as the source's own label CHEMBL269671 ↗ |
| Known as | Artemisinine | ChEMBL registry synonym — accepted as the source's own label CHEMBL269671 ↗ |
| Known as | Artemisininum | ChEMBL registry synonym — accepted as the source's own label CHEMBL269671 ↗ |
| Known as | GNF-PF-5341 | ChEMBL registry synonym — accepted as the source's own label CHEMBL269671 ↗ |
| Known as | Huanghuahaosu | ChEMBL registry synonym — accepted as the source's own label CHEMBL269671 ↗ |
| Known as | NSC-369397 | ChEMBL registry synonym — accepted as the source's own label CHEMBL269671 ↗ |
| Known as | Qing hau sau | ChEMBL registry synonym — accepted as the source's own label CHEMBL269671 ↗ |
| Modality | Small molecule | — CHEMBL269671 ↗ |
| Route | Oral | “500 mg per day for 5 days by oral” NCT04801017 ↗ |